Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.125
Bid: 17.75
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.75 (4.225%)
Open: 18.125
High: 18.125
Low: 18.125
Prev. Close: 18.125
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further sales expansion in Asia

6 Jul 2021 07:00

RNS Number : 2351E
OptiBiotix Health PLC
06 July 2021
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Further sales expansion in Asia

New Exclusive Distribution deal for CholBiome® in South Korea

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has entered a exclusive disbution deal with INSCOBEE INC ("Inscobee") for CholBiome® in the Republic of Korea.

 

Inscobee was established in 1970 and is listed on Korea's major stock market KOSPI since 1985. Its business activities consist of four fast growing business fields: the Smart grid, Mobile Virtual Network Operation, Cosmetics, and Bio-Tech, which includes its pharmaceutical, neutraceuticals, and supplement products with distribution in domestic and overseas markets. Inscobee's group turover was 57.8 billion Korean Won (USD 52.2m) last year and they are curently focused on expanding the health supplement area of their business.

 

Inscobee sell and promote nutraceuticals through hospitals and a consumer distribution base through Korean off-line channels such as Holland & Barrett stores, hypermarkets, home-shopping, and e-commerce channels including on-line malls, open markets, influencer markets and live commerce markets.

 

This agreement with Inscobee is another milestone in a series of deals which ProBiotix have entered into within Asia which help build LP LDL® and CholBiome's reputation and brand awareness in the region and open up the potentail for cross boarder e-commerce trading in China. ProBiotix Health has substantial momentum in the region, according to a recent article published in Nutraingredient Asia: Probiotics and CVD: OptiBiotix extends CholBiome range to APAC as blood pressure and cholesterol concerns rise (nutraingredients-asia.com).

 

Mr. Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health commened: "Incobee is the ideal partner in the fast moving, highly dynamic and competitive South Korean health food markets where consumers seek innovative and effective natural solutions which stand out in the market. We welcome Inscobee into a global team of CholBiome® distributors serving medical doctors and cardiovascular specialists and directly to consumers via homeshopping, pharmacies and medical clinics. By entering deals on CholBiome® and LP LDL® in India, China, Malaysia, Singapore, Indonesia, Phillipines, Taiwan, Australia, and New Zealand, ProBiotix is growing sales and developing a brand presence in these strategically important Asian growth markets."

 

Mr. Seung-Hyeon Nam, Director of Inscobee Plc, commented: "At Inscobee, we are very pleased to introduce CholBiome® products to the Korean healthcare market. We believe CholBiome® has great potential to fill the void of safe and beneficial cardiovascular health needs in the nation and expect that it will play a big role as a flaghship product of Inscobee's healthcare business. We look forward to a long and successful partnership with ProBiotix Health."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

 

 

 

 

   

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUPUMWMUPGGQA
Date   Source Headline
20th Feb 20149:10 amRNSResult of Open Offer and Issue of Equity
3rd Feb 20144:31 pmRNSFurther re Open Offer
30th Jan 20144:37 pmRNSOffer Document Posted
30th Jan 20144:36 pmRNSAnnual Financial Report
28th Nov 20137:00 amRNSChange of Name
26th Nov 20137:00 amRNSChange of Rule 26 Website Address
25th Nov 201311:57 amRNSHolding(s) in Company
20th Nov 20131:21 pmRNSHolding(s) in Company
18th Nov 201312:53 pmPRNNotice of GM and Directorate Change
1st Nov 20134:05 pmPRNPosting of Circular
8th Aug 20137:00 amPRNUpdate
2nd Aug 20137:00 amPRNIssue of Equity - Conversion of Debt, Directors Dealing
25th Apr 20137:00 amPRNHalf-yearly Report
14th Mar 201311:19 amPRNResult of AGM, General Meeting and Issue of Equity
19th Feb 20137:00 amPRNNotice of General Meeting, AGM and Placing
31st Jan 20133:09 pmPRNFinal Results
6th Dec 201212:38 pmRNSNew Contract Win
15th Oct 20128:21 amRNSNew Product Approvals
12th Oct 20127:00 amPRNUpdate and Directorate Changeange
14th Sep 201211:30 amRNSProduct Approval
6th Sep 20127:00 amPRNNew Product Sales
3rd Sep 201210:54 amPRNChange of Adviser
3rd Sep 20128:55 amRNSNew Product Announcement
2nd Jul 20123:56 pmPRNTotal Voting Rights
18th Jun 201211:49 amPRNResult of General Meeting
14th Jun 201210:32 amPRNFurther re placing, update and grant of options
1st Jun 20123:22 pmPRNTotal Voting Rights
24th May 20127:00 amPRNPosting of Circular and change of registered office
22nd May 201211:30 amPRNPlacing and update
30th Apr 201212:00 pmPRNHalf-yearly Report
29th Feb 20121:20 pmPRNTotal Voting Rights
8th Feb 20127:01 amPRNIssue of Equity
8th Feb 20127:00 amPRNTrading Update
24th Jan 20127:00 amPRNHolding(s) in Company
19th Dec 201112:10 pmPRNResult of Annual General Meeting and Statement
2nd Dec 20117:00 amPRNDirectorate change and update
31st Oct 20112:16 pmPRNPosting of report and accounts
28th Oct 20117:00 amPRNFinal Results
23rd Sep 201110:38 amPRNShare Price Movement and Update
9th Sep 20117:00 amPRNFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.